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Continuous Renal Replacement 
Therapy
Basic Therapy Principles
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Is an extracorporeal blood purification therapy intended 
to substitute for impaired renal function over an 
extended period of time and applied for or aimed at 
being applied for 24 hours a day.
* Bellomo R., Ronco C., Mehta R, Nomenclature for Continuous Renal
Replacement Therapies, AJKD, Vol 28, No. 5, Suppl 3, November 1996
Continuous Renal Replacement Therapy 
(CRRT)
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CRRT Goals
•Mimic the functions and physiology of the 
native organ
•Qualitative and quantitative blood 
purification
•Restore and maintain of homeostasis
•Avoid complications and good clinical 
tolerance
•Provide conditions favoring recovery of 
renal function
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Requirements for CRRT
•CRRT requires:
•A central double-lumen veno-venous 
hemodialysis catheter
•An extracorporeal circuit and a 
hemofilter
•A blood pump and a effluent pump.  
•With specific CRRT therapies dialysate 
and/or replacement pumps are required.
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CRRT Modalities
• SCUF- Slow Continuous Ultrafiltration
• Ultrafiltration
• CVVH- Continuous Veno-Venous Hemofiltration
• Convection
• CVVHD- Continuous Veno-Venous Hemodialysis
• Diffusion
• CVVHDF- Continuous Veno-Venous 
Hemodiafiltration
• Diffusion and Convection
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SCUF-Ultrafiltration
•Slow continuous ultrafiltration:
•Requires a blood and an effluent pump.
•No dialysate or replacement solution.
• Fluid removal up to 2 liters/hr can be 
achieved.
•Primary Goal
•Safe management of fluid removal
• Large fluid removal via ultrafiltration
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Transport mechanism: Ultrafiltration
• The movement of fluid through a semi-
permeable membrane driven by a 
pressure gradient (hydrostatic pressure). 
The effluent pump forces plasma water 
and solutes across the membrane in the 
filter. 
• This transport mechanism is used in 
SCUF, CVVH, CVVHD, and CVVHDF.
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CVVH-Convection
•Continuous veno-venous 
hemofiltration
•Requires blood, effluent and 
replacement pumps.
•Dialysate is not required.
•Plasma water and solutes are 
removed by convection and 
ultrafiltration.
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Transport Mechanism: Convection
• Removal of solutes, especially middle and 
large molecules, by convection of relatively 
large volumes of fluid and simultaneous.
• This transport mechanism is used:
• CVVH 
• CVVHDF
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Replacement Fluids
• Physician Rx and adjusted based on pt. clinical 
need.
• Sterile replacement solutions may be:
• Bicarbonate-based or Lactate-based solutions
• Electrolyte solutions
• Must be sterile and labeled for IV Use 
• Higher rates increase convective clearances
• You are what you replace
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CVVHD-Diffusion
•Continuous veno-venous hemodialysis
•Requires the use of blood, effluent and 
dialysis pumps. 
•Replacement solution is not required.
•Plasma water and solutes are removed by 
diffusion and ultrafiltration.
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Transport Mechanisms: Diffusion
• Removal of small molecules by diffusion through 
the addition of dialysate to the fluid side of the filter.
• Dialysate is used to create a concentration gradient 
across a semi permeable membrane
• Dialysis uses a semi permeable membrane for 
selected diffusion
• This transport mechanism is used in:
• CVVHD 
• CVVHDF
© 306100135
Dialysate Solutions
• Through diffusion, dialysate corrects 
underlying metabolic problems
• Dialysate is dependent on buffering 
agent, electrolytes, and glucose
• Dialysate formulas should reflect 
normal plasma values to achieve 
homeostasis
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Bicarbonate Based Solution
•Bicarbonate based solutions are 
physiologic and replace lost 
bicarbonate immediately.
•Effective tool to correct acidosis
•Concentration of  30-35mEq/L 
corrects acidosis in 24 to 48 hours.
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Bicarbonate Based Solution
•Preferred buffer for patients with 
compromised liver function.
•Mean arterial pressure remains stable
•Superior buffer in normalizing 
acidosis without the risk of alkalosis
• Improved hemodynamic stability, and 
fewer cardiovascular events.
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Plasma
PrismaSate
BK0/3.5
PrismaSate
BGK2/0
Calcium Ca2+ (mEq/L) 4.3 - 5.3 3.5 0
Magnesium Mg2+
(mEq/L)
1.5 - 2.5 1.0 1.0
Sodium Na+ (mEq/L) 135 - 145 140 140
Potassium K+ (mEq/L) 3.5 - 5.0 0 2.0
Chloride Cl- (mEq/L) 95 - 108 109.5 108
Lactate (mEq/L) 0.5 - 2.0 3 3
Bicarbonate HCO3
-
(mEq/L)
22 - 26 32 32
Glucose (mg/dL) 65 - 110 0 110
Osmolarity (mOsm/L) 280 - 300 287 292
pH 7.35 - 7.45 ~ 7.40 ~ 7.40
PrismaSate Solution
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Lactate-based Solution
• Metabolized into bicarbonate 
providing it’s under normal 
conditions.
• Lactate is converted in the liver on 
a 1:1 basis to bicarbonate and can 
sufficiently correct acidemia.
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Lactate Based Solution
•Non physiologic pH value of 5.4
• Is a powerful peripheral vasodilator 
•Further acidemia for patients in:
•Hypoxia
• Liver impairment
•Pre-existing lactic acidemia can result in 
worsening of lactic acidemia
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CVVHDF
•Continuous veno-venous hemodiafiltration
•Requires the use of a blood, effluent, dialysate 
and replacement pumps.
•Both dialysate and replacement solutions are 
used.
•Plasma water and solutes are removed by 
diffusion, convection and ultrafiltration.
© 306100135
Transport Mechanisms: 
Diffusion and Convection
• Removal of small molecules by diffusion 
through the addition of dialysate solution.
• Removal of middle to large molecules by 
convection through the addition of 
replacement solution.   
• This transport mechanism is used in:
• CVVHDF
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CRRT Transport Mechanisms
Adsorption
•Molecular adherence to the surface or 
interior of the membrane
•This mechanism is used in:
• SCUF
• CVVH
• CVVHD or CVVHD with ultrafiltration
• CVVHDF
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Principles of CRRT clearance
• CRRT clearance of solute is dependent on 
the following:
• The molecule size of the solute
• The pore size of the semi-permeable 
membrane 
• The higher the ultrafiltration rate (UFR), the 
greater the solute clearance. 
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Principles of CRRT clearance
•Small molecules easily pass through a membrane 
driven by diffusion and convection.
•Middle and large size molecules are cleared 
primarily by convection. 
•Semi-permeable membrane remove solutes with 
a molecular weight of up to 50,000 Daltons.
•Plasma proteins or substances highly protein—
bound will not be cleared. 
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Principles of CRRT clearance
• Sieving Coefficient
• The ability of a substance to pass through a 
membrane from the blood compartment of the 
hemofilter to the fluid compartment.
• A sieving coefficient of 1 will allow free passage of 
a substance; but at a coefficient of 0, the 
substance is unable to pass.
• .94 Na+
• 1.0 K+
• 1.0 Cr
• 0 albumin will not pass
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Vascular Access
•A veno-venous double lumen 
hemodialysis catheter or two single 
lumen venous hemodialysis 
catheters may be used.
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Access Location
• Internal Jugular Vein
• Primary site of choice due to lower associated risk 
of complication and simplicity of catheter insertion. 
• Femoral Vein
• Patient immobilized, the femoral vein is optimal and 
constitutes the easiest site for insertion. 
• Subclavin Vein
• The least preferred site given its higher risk of 
pneumo/hemothorax and its association with 
central venous stenosis.
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Choosing the right catheter
•The length of the catheter chosen will 
depend upon the site used 
• Size of the catheter is important in the pediatric 
population.  
•The following are suggested 
guidelines for the different sites:
•RIJ= 15 cm French
•LIJ= 20 cm French
•Femoral= 25 cm French
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Membrane types and characteristics
• Hemofilter membrane are 
composed of:
• High flux material
• Synthetic/biocompatible material
• Structural design is characterized by:
• High fluid removal 
• Molecular cut-off weight of 30,000-
50,000 Daltons.
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Semi-permeable Membrane
• The semi-permeable membrane 
provides:
• An interface between the blood 
and dialysate compartment.
• Biocompatibility minimizes:
• Severe patient reactions
• Decreases the complement 
activation 
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Complications
• Vascular access 
• Vascular spasm(initial BFR too high)
• Movement of catheter against vessel wall 
• Improper length of hemodialysis catheter 
inserted
• Fluid volume deficit
• Excessive fluid removal without 
appropriate fluid replenishment
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Complications
• Hypotension 
• Intravascular volume depletion
• Underlying cardiac dysfunction
• Electrolyte imbalances 
• High ultrafiltration rates (high clearance)
• Inadequate replenishment of electrolytes by 
intravenous infusion,
• Inadequate replenishment of bicarbonate 
loss during CRRT
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•Acid/base imbalance 
•Renal dysfunction 
• Respiratory compromise
•Blood loss 
• Ineffective anticoagulation therapy
•Clotting of hemofilter
• Inadvertent disconnection in the CRRT system
• Hemorrhage due to over-anticoagulation
• Blood filter leaks
Complications
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Complications
• Air embolus 
• Leaks or faulty connections in tubing 
• Line separation.
• Cardiac arrest 
• Hypotension/hypertension
• Hemolysis
• Air embolism
• Circulatory overload
• Arrhythmias
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Clinical Conditions to Consider
ARF and need for fluid management related 
to:
• SIRS
• Unstable on IHD
• Organ transplants
• CHF /volume overload
• Post CV surgery
• Post trauma patients
• Severe Burns
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Fluid Management in CRRT
Goal of Fluid Management
• “The patient will achieve and maintain 
fluid volume balance within planned or 
anticipated goals”
(ANNA Standards of Clinical Practice for 
Continuous Renal Replacement 
Therapy”)
Considerations
• Intakes and outputs (I&O)
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I & O Formula
Net fluid removal hourly (physician order)
+
Nonprisma intake (IV, TPN, etc.)
-
Nonprisma output (urine, etc.)
=
Patient Fluid Removal Rate (set in prisma)
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Hypothermia in CRRT
Causes
• Patient’s blood in extracorporeal circuit at 
room temperature
• Administration of large volumes of room 
temperature fluids (replacement and dialysate)
Signs and Symptoms
• Hemodynamic instability
• Chilling, shivering
• Skin pallor, coolness and cyanosis
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Hypothermia
Treatment measures
•Warming blankets
•Prismatherm™ II Blood Warmer
•Prismaflo® Blood Warmer
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Initiation of Therapy
• Assess and record the patient’s vital signs and 
hemodynamic parameters prior to initiation of 
therapy.
• Review physician orders and lab data
• Prepare vascular access using unit protocol.
• Set fluid removal, dialysate and replacement 
solution flow rates as prescribed.
• Administer anticoagulant and initiate infusion if 
applicable.
• Document patient’s hemodynamic stability with 
initiation of therapy.
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Intratherapy Monitoring
The critical care nurse must continuously monitor the 
following parameters during CRRT
• Blood pressure
• Patency of circuit
• Hemodynamic stability
• Level of 
consciousness
• Acid/base balance
• Electrolyte balance
• Hematological status
• Infection
• Nutritional status
• Air embolus
• Blood flow rate
• Ultrafiltration flow rate
• Dialysate/replacement 
flow rate
• Alarms and responses
• Color of 
ultrafiltrate/filter blood 
leak
• Color of CRRT circuit
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Termination of Therapy
• The decision to terminate CRRT is made 
by the nephrologist or an intensivist 
based on the patient’s renal recovery or 
the patient’s status-recovery or decision 
of the patient and family.
• Extracorporeal circuit will be 
discontinued as per established 
protocol.
• Vascular access care administered as 
per unit protocol
Current Research
FAQs
How much replacement and 
dialysate do you use?
Ronco’s research
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Effects of different doses in CVVH on outcome of ARF - Ronco & Bellomo 
study. Lancet . july 00
Prospective study on 425 patients - 3 groups:
Study: 
• survival after 15 days of HF stop
• recovery of renal function
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Effect of BUN at CVVH Initiation on Survival
80
70
60
50
40
30
20
10
0
Group 1 Group 2 Group 3
Survivors Non Survivors
p < 0.01
B
lo
o
d
 U
re
a
 N
it
ro
g
e
n
 (
m
g
/d
l)
p < 0.01 p < 0.01
Effects of different doses in CVVH on outcome of ARF - Ronco & Bellomo 
study. Lancet . july 00
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RIFLE Criteria
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RIFLE Stratification in Patients Treated 
with CRRT
Bell et al, Nephrol Dial Transplant 2005
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Conclusions:
An increased treatment dose from 20 ml/h/kg to 35 ml/h/kg 
significantly improved survival.
A delivery of 45ml/kg/hr did not result in further benefit in 
terms of survival, but in the septic patient an 
improvement was observed. 
Our data suggest an early initiation of treatment and a 
minimum dose delivery of 35 ml/h/kg (ex. 70 kg patient 
= 2450 ml/h) improve patient survival rate.
Effects of different doses in CVVH on outcome of ARF - Ronco & Bellomo study. Lancet . july 00
Renal Recovery? 
CRRT does affect resumption of function.
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By avoiding hypotensive episodes, 
the risk of further kidney damage is 
reduced and the chance for renal 
recovery is enhanced
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Manuscript under review
Leading the way…
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CRRT vs. IHD in Renal Recovery
Recent studies suggest that CRRT is superior to IHD with 
respect to recovery of renal function
Implications go far beyond just “hard” endpoint of renal 
recovery 
• Need for chronic dialysis impairs quality of life
• If length of stay (LOS) in ICU can be reduced this will have a 
major impact on hospital budget
• Patients dependent on chronic dialysis will consume significant 
health care resources and have an impact on the community 
health care budget
Leading the way…
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Questions?
